While one of the challenging clinical issues in MASH arises from lack of biomarkers (Ramai et al, 2021), our studies of human samples showed that the circulatory levels of PCPE-1 increased in patients with MASH in both BMI-adjusted (BMI < 25) and non-BMI-adjusted groups (Fig. 1N; Appendix Fig. S1A,B, Table 1), thus suggesting a role for PCPE-1 as a biomarker for this condition. This evidence concerns the gene PCOLCE and metabolic dysfunction-associated steatohepatitis.